Johnson & Johnson (JNJ) Current Assets (2009 - 2026)
Johnson & Johnson (JNJ) posted Current Assets of $59.2 billion for Q1 2026, up 6.38% sequentially from $55.6 billion in Q4 2025, and down 17.3% YoY from $71.6 billion in Q1 2025.
Johnson & Johnson (JNJ) Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Current Assets data on file, last reported at $59.2 billion in Q1 2026.
- Quarterly Current Assets fell 17.3% year-over-year to $59.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.2 billion (down 17.3% YoY) and the FY2025 annual result came in at $55.6 billion, changed 0.48% from the prior year.
- Current Assets grew to $59.2 billion in Q1 2026 per JNJ's latest filing, from $55.6 billion in the prior quarter.
- The five-year high for Current Assets was $71.6 billion in Q1 2025, with the low at $53.2 billion in Q3 2024.
- Average Current Assets over 5 years is $58.7 billion, with a median of $57.4 billion recorded in 2024.
- Year-over-year, Current Assets decreased 17.68% in 2023 and increased 25.52% in 2025.
- Johnson & Johnson's Current Assets stood at $65.2 billion in 2022, then slipped by 18.0% to $53.5 billion in 2023, then advanced by 4.48% to $55.9 billion in 2024, then slipped by 0.48% to $55.6 billion in 2025, then gained by 6.38% to $59.2 billion in 2026.
- Business Quant data shows JNJ's Current Assets at $59.2 billion in Q1 2026, $55.6 billion in Q4 2025, and $54.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 54.84 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 59.17 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 9.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 59.17 Bn |
| Dec 28, 2025 | 55.62 Bn |
| Sep 28, 2025 | 54.61 Bn |
| Jun 29, 2025 | 54.50 Bn |
| Mar 30, 2025 | 71.55 Bn |
| Dec 29, 2024 | 55.89 Bn |
| Sep 29, 2024 | 53.25 Bn |
| Jun 30, 2024 | 57.82 Bn |
| Mar 31, 2024 | 57.00 Bn |
| Dec 31, 2023 | 53.50 Bn |
| Oct 1, 2023 | 53.70 Bn |
| Jul 2, 2023 | 60.57 Bn |
| Apr 2, 2023 | 64.39 Bn |
| Jan 1, 2023 | 55.29 Bn |
| Oct 2, 2022 | 65.24 Bn |
| Jul 3, 2022 | 63.85 Bn |
| Apr 3, 2022 | 60.42 Bn |
| Jan 2, 2022 | 60.98 Bn |
| Oct 3, 2021 | 59.89 Bn |
| Jul 4, 2021 | 53.77 Bn |